Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Protara Therapeutics, Inc. (PRTO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/03/2023 |
8-K
| Quarterly results |
| 11/03/2022 |
8-K
| Quarterly results |
| 08/09/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 03/09/2022 |
8-K
| Quarterly results |
| 11/04/2021 |
8-K
| Quarterly results |
| 08/05/2021 |
8-K
| Quarterly results |
| 10/31/2019 |
8-K
| Quarterly results |
| 08/07/2019 |
8-K
| Quarterly results |
| 05/08/2019 |
8-K
| Quarterly results |
| 03/13/2019 |
8-K
| Quarterly results |
| 11/07/2018 |
8-K
| Quarterly results|
Docs:
|
"Proteon Therapeutics Announces Third Quarter 2018 Financial Results WALTHAM, Mass., Nov. 07, 2018 -- Proteon Therapeutics, Inc. , a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended September 30, 2018, and recent business highlights. “We made excellent progress in the third quarter of 2018,” said Timothy Noyes, President and Chief Executive Officer of Proteon. “We remain on track to release top-line data from the Phase 3 PATENCY-2 clinical trial in March 2019 and to file a BLA later in 2019 if the results are positive. We continue preparing to build the commercial infrastructure to launch investigational vonapanitase, if approved by FDA.” Recent Highli..." |
|
| 08/07/2018 |
8-K
| Quarterly results |
| 05/09/2018 |
8-K
| Quarterly results|
Docs:
|
"Proteon Therapeutics Announces First Quarter 2018 Financial Results WALTHAM, Mass., May 09, 2018 -- Proteon Therapeutics, Inc. , a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended March 31, 2018, and recent business highlights. “I am pleased by our team’s many accomplishments in the first quarter of 2018, which keep Proteon on track for a potential BLA filing in 2019,” said Timothy Noyes, President and Chief Executive Officer of Proteon. “Most importantly, we completed enrollment in PATENCY-2, our ongoing Phase 3 trial of vonapanitase. We also completed our drug substance process validation runs at Lonza’s facility in Visp, Switzerland, and executed a..." |
|
| 03/14/2018 |
8-K
| Quarterly results|
Docs:
|
"Proteon Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results WALTHAM, Mass., March 14, 2018 -- Proteon Therapeutics, Inc. , a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the year ended December 31, 2017, and recent business highlights. “With enrollment completed on schedule in PATENCY-2, our second Phase 3 clinical trial of investigational vonapanitase, we are now focused on study follow-up and preparing for a potential BLA filing in the fourth quarter of 2019,” said Timothy Noyes, President and Chief Executive Officer of Proteon. “Also, with sufficient capital to fund the Company’s operations into the fourth quarter of 2019, we continue devo..." |
|
| 11/07/2017 |
8-K
| Quarterly results |
| 08/07/2017 |
8-K
| Quarterly results|
Docs:
|
"Proteon Therapeutics Announces Second Quarter 2017 Financial Results WALTHAM, Mass., Aug. 07, 2017 -- Proteon Therapeutics, Inc. , a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced financial results for the quarter ended June 30, 2017, and recent business highlights. “Our productive dialogue with the FDA has created a clear path forward for vonapanitase, and we believe the decision by the FDA to grant vonapanitase a Breakthrough Therapy designation speaks to the clinical importance of fistula survival and use for hemodialysis to patients with chronic kidney disease,” said Timothy Noyes, President and Chief Executive Officer of Proteon. “In addition, we are pleased to have closed earlier this m..." |
|
| 05/10/2017 |
8-K
| Form 8-K - Current report |
| 03/16/2017 |
8-K
| Form 8-K - Current report |
| 11/07/2016 |
8-K
| Quarterly results|
Docs:
|
"Proteon Therapeutics Announces Third Quarter 2016 Financial Results WALTHAM, Mass., Nov. 07, 2016 -- Proteon Therapeutics, Inc. , a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended September 30, 2016, and recent business highlights. “We are making strong progress in our Phase 3 program for investigational vonapanitase,” said Timothy Noyes, President and Chief Executive Officer of Proteon. “PATENCY-1 top-line results are expected in December, and our second Phase 3 trial, PATENCY-2, is on track to complete patient enrollment in the first quarter of 2017.” Recent Highlights for 2016 Overview of Phase 1 clinical program of vonapanitase in peripheral arte..." |
|
|
|